The Role of the Renin-Angiotensin System in Cisplatin Nephrotoxicity

References

• Loehrer P J, Einhorn L H. Cisplatin. Ann Intern Med 1984; 100: 704–707
   PubMed Web of Science ®Google Scholar
• Rossof A H, Salyton R E, Perla C P. Preliminary clinical experience with cis-diamminedichloroplatinum II. Cancer 1977; 30: 1451–1456
   Google Scholar
• Daugaard G, Abildgaard U, Holstein-Rathlou N H, Amtorp O, Leyssac P P. Effect of cisplatin on haemo-dynamics and tubular function in the dog kidney. Int J Androl 1987; 10: 347–351
   PubMedGoogle Scholar
• Offerman J JG, Meijer S, Sleijfer D TH, Mulder N H, Donker A MJ, Schraffordt-Koops H, Van der Hem G K. Acute effect of cis diamminedichloroplatinum (CDDP) on renal function. Cancer Chemother Pharmacol 1984; 12: 36–38
   PubMed Web of Science ®Google Scholar
• Goldstein R S, Noordeweir B, Bond J J, Hook J B, Mayor G H. cis-Dichlorodiammineplatinum nephrotoxicity: time course and dose response of renal function impairment. Toxicol Appl Pharmacol 1981; 60: 163–175
   PubMed Web of Science ®Google Scholar
• Fillastre J P, Raguenez-Viotte G. Cisplatin nephrotoxicity. Toxicol Lett 1989; 46: 163–175
   PubMed Web of Science ®Google Scholar
• Anand A J, Bashey B. Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 1993; 27: 1519–1525
   PubMed Web of Science ®Google Scholar
• Ormond P M, Basinger M A, Jones M M, Hande K R. Association between increased atrial natriuretic peptide and reduced cisplatin nephrotoxicity in rats. J Pharmacol Exp Ther 1992; 262: 246–251
   PubMed Web of Science ®Google Scholar
• Deegan P M, Basinger M A, Jones M M, Hande K R. Atrial natriuretic peptide reduces the nephrotoxicity but not the anti-tumour activity of cisplatin. Br J Pharmacol 1992; 107: 40
   Web of Science ®Google Scholar
• Burnett J C, Granger J P, Opgenorth T J. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 1984; 247: F863–F866
   PubMed Web of Science ®Google Scholar
• Harris P G, Thomas D, Morgan T O. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 1987; 326: 697–698
   PubMed Web of Science ®Google Scholar
• de Arriba G, Barrio V, Olivera A, Rodriguez-Puyol D, Lopez-Novoa J M. Atrial natriuretic peptide inhibits angiotensin II-induced contraction of isolated glomeruli and cultured glomerular mesangial cells of rats. J Lab Clin Med 1988; 111: 466–474
   PubMed Web of Science ®Google Scholar
• Waldman S A, Murad F. Cyclic GMP synthesis and function. Pharmacol Rev 1987; 39: 163–196
   PubMed Web of Science ®Google Scholar
• Morin J P, Thomas N, Toutain H, Borghi H, Fillastre J P. Modulation of gentamicin nephrotoxicity by chronic inhibition of angiotensin-I-converting enzyme in rat. Arch Toxicol 1989; 63: 47–53
   PubMed Web of Science ®Google Scholar
• Seelig C B, Maloley P A, Campbell J R. Nephrotoxicity associated with concommitant ACE inhibitor and NSAID therapy. South Med J 1990; 83: 1144–1148
   PubMed Web of Science ®Google Scholar
• Banos E JG, Boim M A, Ajzen H, Ramos L O, Schol N. Glomerular haemodynamics and hormonal participation on cyclosporine nephrotoxicity. Kidney Int 1987; 32: 19–25
   PubMed Web of Science ®Google Scholar
• McAuley F T, Whiting P H, Thomson A W, Simpson J G. The influence of enalapril or sprinolactone on experimental cyclosporine nephrotoxicity. Biochem Pharmacol 1987; 36: 699–703
   PubMed Web of Science ®Google Scholar
• Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity: insights into mechanism. Int J Androl 1987; 10: 325–346
   PubMedGoogle Scholar
• Cushman D W, Ondetti M A. Inhibitors of angiotensin converting enzyme. Prog Med Chem 1980; 17: 41–103
   PubMedGoogle Scholar
• Pettinger W A, Mitchell H C. Clinical pharmacology of angiotensin antagonists. Fed Proc 1976; 35: 2521–2525
   PubMedGoogle Scholar
• Fenoy F J, Milicic I, Smith R D, Wong P C, Timmermans P BMWM, Roman R. Effects of DuP753 on renal function of normotensive and spontaneously hypertensive rats. Am J Hypertens 1991; 4: 321s–326s
   Web of Science ®Google Scholar
• Raya T E, Fonken S J, Lee R W, Daugherty S, Goldman S, Wong P C, Timmermans P BMWM, Morkin E. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of hypertension. Am J Hypertens 1991; 4: 334s–340s
   PubMed Web of Science ®Google Scholar
• Fontoura B MA, Nussenzveig D R, Timmermans P BMWM, Maack T. DuP 753 is a potent nonpeptide antagonist of angiotensin II receptors on isolated perfused rat kidney and cultured renal cells. Am J Hypertens 1991; 4: 303s–308s
   Web of Science ®Google Scholar
• Loutzenhiser R, Epstein M, Hayashi K, Takenaka T, Forster H. Characterization of the renal microvascular effects of angiotensin II antagonist DuP 753: Studies in isolated perfused hydronephrotic kidneys. Am J Hypertens 1991; 4: 309s–314s
   Web of Science ®Google Scholar
• Cogan M C, Xie M H, Liu F Y, Wong P C, Timmermans P BMWM. Effects of DuP 753 on proximal nephron and renal transport. Am J Hypertens 1991; 4: 315s–320s
   PubMed Web of Science ®Google Scholar
• Leroy A F, Wehling M L, Sponseller H L, Litterst C L, Gram T E, Guarino A M, Becher D A. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 1977; 18: 184–191
   PubMedGoogle Scholar
• Thomson A W, McAuley F T, Whiting P H, Simpson J G. Angiotensin-converting enzyme inhibition or aldosterone antagonism reduces cyclosporine nephrotoxicity in the rat. Transplant Proc 1987; 19: 1242–1243
   PubMed Web of Science ®Google Scholar
• Ozols R F, Corden B J, Jacobs J, Wesley M N, Ostchegas Y, Young R C. High dose cisplatin in hypertonic saline. Ann Int Med 1984; 100: 19–24
   PubMed Web of Science ®Google Scholar
• Ammer U, Natochin Y, David C, Rumrich G, Ullrich K J. Cisplatin nephrotoxicity: site of functional disturbance and correlation to loss of body weight. Renal Physiol Biochem 1993; 16: 131–145
   PubMedGoogle Scholar
• Valentovic M A, Scott L A, Madan E, Yokel R A. Renal accumulation and urinary excretion of cisplatin in diabetic rats. Toxicology 1991; 70: 151–162
   PubMed Web of Science ®Google Scholar
• Kato J, Kida O, Higa T, Sasaki A, Kondo K, Miyata A, Kangawa K, Matsuo H, Tanaka K. Increase in plasma atrial natriuretic polypeptide (ANP) following sodium load in anesthetized rats. Life Sci 1986; 39: 493–497
   PubMed Web of Science ®Google Scholar
• Hayes D M, Cvitkovie E, Gobley R B, Scheiner E, Helson L, Krakoff I. High dose of cis-platinum diammine dichloride. amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372–1381
   PubMed Web of Science ®Google Scholar
• Kurnik B RC, Weisberg L S, Askenase A D, Kurnik P B. Mannitol stimulates atrial natriuretic peptide release in humans. Am J Kidney Dis 1991; 17: 62–68
   PubMed Web of Science ®Google Scholar
• Akabane S, Imanishi M, Matsushima Y, Kawamura M, Kuramochi M, Ito K, Omae T. Renal actions of atrial peptide on the postischemic kidney. Can J Physiol Pharm 1988; 66: 601–607
   PubMed Web of Science ®Google Scholar
• Kurnik B RC, Weisberg L S, Cuttler I M, Kurnik P B. Effects of atrial natriuretic peptide versus mannitol on renal blood flow during radio-contrast infusion in chronic renal failure. J Lab Clin Med 1990; 116: 27–35
   PubMed Web of Science ®Google Scholar
• Capasso G, Anastasio P, Giordano D, Albarano L, Desanto N G. The beneficial effect of atrial natriuretic peptide on cisplatin-induced nephrotoxicity. Am J Nephrol 1987; 7: 228–234
   PubMed Web of Science ®Google Scholar
• Ormond P M, Hande K R. Atrial naturetic peptide protects against cisplatin nephrotoxicity in rats. Proc Am Assoc Cancer Res 1992; 33: 534
   Google Scholar
• Dunn B R, Ichikawa I, Pfeffer J M, Troy J L, Brenner B M. Renal and systemic hemodynamic effects of synthetic atrial natriuretic peptide in the anesthetized rat. Circ Res 1986; 59: 237–246
   PubMed Web of Science ®Google Scholar
• Knepper M A, Lankford S P, Terada Y. Renal tubular actions of ANF. Can J Physiol Pharm 1990; 69: 1537–1545
   Web of Science ®Google Scholar
• Herblin W F, Chiu A T, McCall D E, Ardecky R J, Carini D J, Duncia J V, Pease L J, Wong P C, Wexler R R, Johnson A J, Timmermans P BMWM. Angiotensin II receptor heterogeneity. Am J Hypertens 1991; 4: 299s–302s
   PubMed Web of Science ®Google Scholar
• Chiu A T, McCall D E, Price W A, Wong P C, Carini D J, Duncia J V, Wexler R R, Yoo S E, Johnson A J, Timmermans P BMWM. In vitro pharmacology of DuP 753. Am J Hypertens 1991; 4: 282s–287s
   PubMed Web of Science ®Google Scholar
• Chiu A T, McCall D E, Price W A. Nonpeptide angiotensin II receptor antagonists. VII. cellular and biochemical pharmacology of DuP753, an orally active anti-hypertensive agent. J Pharmacol Exp Ther 1990; 252: 711–718
   PubMed Web of Science ®Google Scholar
• Wong P C, Price W A, Chiu A T, Carini D J, Duncia J V, Johnson A L, Wexler R R, Timmermans P BMWM. Nonpeptide angiotensin II receptor antagonists: studies with EXP9270 and DuP 753. Hypertension 1990; 15: 823–834
   PubMed Web of Science ®Google Scholar
• Chiu A T, Roscoe W A, McCall D E, Timmermans P BMWM. Angiotensin II-I receptors mediate both the vasoconstriction and cellular hypertrophy in rat aortic smooth muscle cells. Receptor 1991; 1: 133–140
   PubMedGoogle Scholar
• Wong P C, Price W A, Chiu A T, Duncia J V, Carini D J, Wexler R R, Johnson A L, Timmermans P BMWM. In vivo pharmacology of DuP 753. Am J Hypertens 1991; 4: 288s–298s
   PubMedGoogle Scholar
• Wong P C, Price W A, Chiu A T, Carini D J, Duncia J V, Johnson A L, Wexler R R, Timmermans P BMWM. Nonpeptide angiotensin II receptor antagonists: studies with EPS9270 and DuP 753. Hypertension 1990; 15: 823–834
   PubMed Web of Science ®Google Scholar
• DeWitt L M, Jones T W, Moore L. Stimulation of the renal endoplasmic reticulum calcium pump: a possible biomarker for platinum toxicity. Toxicol Appl Pharmacol 1988; 92: 157–169
   PubMed Web of Science ®Google Scholar
• Jones M M, Basinger M A, Craft W D, Domingo J L, Llobet J M. Control of some aspects of cis-platinum nephrotoxicity. Arch Toxicol 1986; 59: 167–171
   PubMed Web of Science ®Google Scholar
• Jones M M, Basinger M A, Holscher M A. Relative effectiveness of some compounds for the control of cisplatin-induced nephrotoxicity. Toxicology 1991; 68: 227–247
   PubMed Web of Science ®Google Scholar
• Treskes M, Boven E, Holwerda V, Pinendo M, Wim J F. Time-dependence in the selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse. Cancer Res 1992; 52: 2257–2260
   PubMed Web of Science ®Google Scholar
• Burdmann E A, Andoh T, Lindsley J, Evan A, Elzinga L, Bennett W M. Blockade of the renin angiotensin system (RAS) in chronic cyclosporine (CSA) nephrotoxicity. FASEB J 1993; 7: A572
   PubMed Web of Science ®Google Scholar
• Wolf G, Neilson E G. Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol 1990; 259: F768–F777
   PubMed Web of Science ®Google Scholar
• Miller P L, Rennke H G, Meyer T W. Glomerular hypertrophy accelerates hypertensive glomerular injury in rats. Am J Physiol 1991; 261: 459–465
   PubMed Web of Science ®Google Scholar
• Smith L J, Rosenberg M E, Hostetter T H. Effect of angiotensin II blockade on dietary protein-induced renal growth. Am J Kidney Dis 1993; 22: 120–127
   PubMed Web of Science ®Google Scholar
• Fogo A, Yoshida Y, Yared A, Ichikawa I. Importance of angiogenic action of angiotensin II in the glomerular growth of maturing kidneys. Kidney Int 1990; 38: 1068–1074
   PubMed Web of Science ®Google Scholar
• Wolf G. Regulating factors of renal tubular hypertrophy. Clin Invest 1993; 71: 867–870
   PubMedGoogle Scholar
• Ganz M B, Pekar S K, Perfetto M C, Sterzel R B. Arginine vasopressin promotes growth of rat glomerular mesangial cells in culture. Am J Physiol 1988; 255: F898–906
   Google Scholar
• Simonson M S, Wann S, Mene P, Dubyak G R, Kester M, Nakazato Y, Sedor J R, Dunn M J. Endothelin stimulates phospholipase C, Na+/H+ exchange, c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest 1989; 83: 708–712
   PubMed Web of Science ®Google Scholar
• Johnson A, Lermioglu F, Garg U C, Morgan-Boyd R, Hassid A. A novel biological effect of atrial natriuretic hormone: inhibition of mesangial cell mitogenesis. Biochem Biophys Res Commun 1988; 152: 893–897
   PubMed Web of Science ®Google Scholar
• Garg U C, Hassid A. Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am J Physiol 1989; 257: F60–F66
   Google Scholar